Lexaria Bioscience Corp
Lexaria Bioscience Corp (LEXX) is a small-cap biotechnology company developing DehydraTECH, a proprietary drug-delivery platform designed to improve the oral absorption and onset of active molecules such as cannabinoids, nicotine, vitamins and select pharmaceuticals. The company licenses its technology to partners and pursues clinical studies to validate performance claims. With a market capitalisation of about $20.15m, Lexaria remains an early-stage, development-focused business with limited commercial revenue and a modest balance sheet. Investors should weigh the potential of platform-enabled royalties and licensing revenue against clear risks: clinical or regulatory setbacks, slow partner uptake, financing needs and share-price volatility common to micro-cap biotechs. This summary is general, educational information only and not personal investment advice. Suitability depends on an individual’s risk tolerance, investment horizon and financial circumstances; consider seeking independent financial advice before investing. Past performance, if any, is not a reliable guide to future results and values can fall as well as rise.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Lexaria Bioscience's stock with a target price of $9, indicating strong potential for growth.
Financial Health
Lexaria Bioscience is generating strong revenue and cash flow with exceptional profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring LEXX
Next-Generation Drug Delivery Systems
This carefully selected group of stocks represents innovative companies revolutionizing how medications are delivered to patients. Handpicked by our professional analysts, these firms are developing technologies that make treatments simpler, more effective, and user-friendly, creating meaningful investment potential in an evolving healthcare landscape.
Published: July 18, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Delivery tech focus
DehydraTECH is the company’s core asset and explains investor interest; potential licensing revenue exists, though clinical and commercial success are not guaranteed.
Clinical progress matters
Trial results and regulatory updates can materially affect prospects; positive data may drive interest, while setbacks can hurt valuation.
Small‑cap volatility
With a market cap around $20m, Lexaria is a micro‑cap and may show large price swings and liquidity limits—suitability depends on risk tolerance.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
